GO
Loading...

Pharmaceuticals

More

  • Bristol-Myers Profit Jumps on Higher Drug Revenue Thursday, 25 Oct 2007 | 9:00 AM ET

    Bristol-Myers Squibb Thursday said third-quarter earnings more than doubled on higher drug revenue, including a strong rebound for its Plavix blood-clot preventer, and raised its 2007 profit forecast.

  • Eli Lilly Halts Two Drug Studies; Shares Fall Wednesday, 24 Oct 2007 | 6:50 PM ET

    Eli Lilly said it stopped giving its experimental blood-clot preventer prasugrel to heart patients in two small trials, noting that the dosage of the drug may have to be adjusted for certain types of patients.

  • Amgen: Is There A Takeout Scenario? Wednesday, 24 Oct 2007 | 1:15 PM ET

    On a day when the markets are selling off, shares of the world's biggest biotech company--by sales--are holding their own. There are a few things that could be buoying Amgen's stock. The company won a huge patent battle yesterday, it reports earnings after the closing bell today and an analyst has upgraded the stock to "Outperform".

  • European Stocks Close Lower after US Housing Slowdown Wednesday, 24 Oct 2007 | 12:18 PM ET

    Major European indexes closed lower after U.S. existing-homes sales fell 8% in September to a record low 5.04 million unit because of troubles in the subprime mortgages and credit markets.

  • Glaxo's Avandia Nose Dive: What It Means Wednesday, 24 Oct 2007 | 11:48 AM ET

    Shares in the world's second biggest drug company, GlaxoSmithKline, are giving back all of yesterday's gains in early trading this morning. That's because sales of its embattled diabetes drug, Avandia and other Avandia-related products took a huge dive in the third quarter. Down 48% in the U.S. from the same time last year.

  • Glaxo Profit Hit by Avandia Sales Slump Wednesday, 24 Oct 2007 | 11:46 AM ET
    The company logo of GlaxoSmithKline, is seen on the headquarters building in London, Wednesday May 10, 2006. GlaxoSmithKline PLC said Wednesday it has been granted a High Court injunction against animal rights activists who sent threats to the drugmaker's shareholders, barring them from sending more letters or revealing private information about the investors. (AP Photo/Alastair Grant)

    GlaxoSmithKline posted a lower profit on Wednesday due to tumbling sales of its Avandia diabetes drug, generic competition and pressure on top-selling asthma treatment Advair, and said it would cut jobs to save costs.

  • Cancer Drug Erbitux Helps German Merck's Results Wednesday, 24 Oct 2007 | 5:42 AM ET

    German pharmaceutical and chemical company Merck KGaA said Wednesday that its third-quarter profit fell 75 percent because of costs related to its purchase of Swiss biotech firm Serono.

  • Drugmaker Match Game Tuesday, 23 Oct 2007 | 6:41 PM ET

    Does Big Pharma need a modern day match-maker? With so many weak pipelines, the Fast Money traders think some could use a mate!

  • Dendreon's Provenge Trial: Big Step On Bumpy Road Tuesday, 23 Oct 2007 | 2:58 PM ET

    It isn't moving the stock, but Dendreon this morning announced that it has signed up all of the patients for the big clinical trial that could lead to its prostate cancer drug, Provenge, winning Food and Drug Administration approval. The completion of enrollment was not unexpected, so that's why people aren't trading on the news.

  • Amgen Wins Patent Suit Over Anemia Drug Tuesday, 23 Oct 2007 | 1:00 PM ET

    A Boston jury Tuesday found  that the patents on Amgen's top-selling anemia drugs are valid, blocking Roche from launching a rival medicine in the United States and sending Amgen shares up more than 2 percent.

  • Biogen Idec Earnings A 'Huge Swing and a Miss' Tuesday, 23 Oct 2007 | 12:13 PM ET

    Biotech giant Biogen Idec posted some disappointing third-quarter results, falling short of Wall Street expectations across the board. Does it matter, since the company has announced it's up for sale? Biotech analyst Christopher Raymond of Robert W. Baird thinks it does.

  • Cramer: Be Patient with Schering-Plough Tuesday, 23 Oct 2007 | 10:20 AM ET

    SGP took a beating after it missed its earnings, but investors shouldn't lose hope. Cramer talks to CEO Fred Hassan to find out what's on the horizon.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Biogen Earnings Fall Short of Analysts' Targets Tuesday, 23 Oct 2007 | 9:51 AM ET

    Biotechnology company Biogen Idec, which put itself up for sale earlier this month, reported third-quarter earnings and revenue Tuesday that fell short of analysts' expectations.

  • Schering Plough Shares Sheared Monday, 22 Oct 2007 | 1:37 PM ET

    What can I say? I love alliteration. But investors in the drugmaker are probably in no mood for a cute, clever turn of phrase. SGP is absolutely getting hammered this morning after coming in with third quarter earnings below expectations.

  • Pharma Stock Picks From a Five-Star Fund Manager Monday, 22 Oct 2007 | 1:05 PM ET

    To a five-star fund manager, it's not how big the stars are, but how brightly they're shining.  In the pharmaceutical field, Kris Jenner of T. Rowe Price finds brightness at both ends of the size spectrum.

  • Safety After Sudden Sell-Off Monday, 22 Oct 2007 | 11:41 AM ET

    Will Friday’s sell-off have a dramtaic impact on Monday's trading and the earnings flood that lies ahead?

  • Schering Results Miss Targets; Shares Plunge Monday, 22 Oct 2007 | 10:27 AM ET

    Schering-Plough on Monday reported third-quarter profit and sales that fell short of Wall Street's target, sending shares down more than 10 percent amid concerns about its flagship cholesterol drugs

  • Merck's Profit Jumps 62%; Drug Maker Raises Outlook Monday, 22 Oct 2007 | 9:40 AM ET

    Merck reported a better-than-expected profit, helped by sales of its vaccines and cholesterol drugs, and raised its 2007 profit forecast in view of strong current trends.

  • Genentech And Readers Not Seeing Eye To Eye Friday, 19 Oct 2007 | 8:04 AM ET

    My recent posts on Genentech trying to crack down on doctors using its cheaper cancer drug Avastin instead of the more expensive Lucentis to treat patients with age-related macular degeneration--elicited a lot of emails from readers all over the world.

  • Gilead HIV Drugs Drive Profit After Year-Ago Loss Thursday, 18 Oct 2007 | 7:17 PM ET

    Gilead Sciences posted a third-quarter profit that topped Wall Street targets on Thursday, on sales of drugs that fight the virus that causes AIDS, compared with a year-ago net loss due to acquisition- related costs.